Bioline RX Ltd (BLRX) EPS Estimated At $-0.05

November 15, 2017 - By Marguerite Chambers

 Bioline RX Ltd (BLRX) EPS Estimated At $ 0.05

Investors wait Bioline RX Ltd (NASDAQ:BLRX) to report on November, 21 before the open. its quarterly earnings Wall Street analysts expect $-0.05 EPS, up $0.03 or 37.50 % from last year’s $-0.08 same quarter earnings. Bioline RX Ltd’s Wall Street analysts see 0.00 % EPS growth, taking into account the $-0.05 EPS reproted in the previous quarter, About 88,507 shares traded. Bioline RX Ltd (NASDAQ:BLRX) has declined 6.10% since November 15, 2016 and is downtrending. It has underperformed by 22.80% the S&P500.

Bioline RX Ltd (NASDAQ:BLRX) Ratings Coverage

Among 6 analysts covering BioLineRx (NASDAQ:BLRX), 6 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. BioLineRx had 17 analyst reports since July 27, 2015 according to SRatingsIntel. The firm earned “Buy” rating on Tuesday, September 26 by H.C. Wainwright. The rating was maintained by Oppenheimer on Tuesday, August 8 with “Buy”. The stock of Bioline RX Ltd (NASDAQ:BLRX) earned “Buy” rating by Maxim Group on Tuesday, August 8. The rating was downgraded by Maxim Group on Friday, August 12 to “Hold”. The company was maintained on Friday, May 26 by H.C. Wainwright. Maxim Group maintained it with “Buy” rating and $300 target in Thursday, June 1 report. Oppenheimer maintained Bioline RX Ltd (NASDAQ:BLRX) on Tuesday, September 12 with “Buy” rating. On Wednesday, March 9 the stock rating was maintained by JMP Securities with “Market Outperform”. H.C. Wainwright maintained Bioline RX Ltd (NASDAQ:BLRX) on Wednesday, August 9 with “Buy” rating. Roth Capital initiated it with “Buy” rating and $300 target in Thursday, August 3 report.

BioLine RX Ltd is an Israel-based company engaged in the development of therapeutics, from preclinical-stage development to advanced clinical trials, for a range of medical needs. The company has market cap of $97.67 million. The Company’s clinical therapeutic candidates under development consist of BL-1020 that is in Phase II/III clinical trials to improve cognitive function in schizophrenia patients; BL-1040, which is under pivotal CE-Mark registration trial for the prevention of cardiac remodeling following an acute myocardial infarction; BL-5010, which has completed Phase I/II clinical trials for non-surgical removal of skin lesions; BL-1021 that has completed Phase Ia clinical trial for the treatment of neuropathic pain or pain that results from damage to nerve fibers, and BL-7040, a synthetic oligonucleotide, which is in Phase II clinical trial for the treatment of inflammatory bowel disease. It currently has negative earnings.

More notable recent Bioline RX Ltd (NASDAQ:BLRX) news were published by: Prnewswire.com which released: “BioLineRx to Report Third Quarter 2017 Results on November 21, 2017” on November 09, 2017, also Seekingalpha.com with their article: “BioLineRx: Why I See Significant Upside Potential In This $1 Biotech Stock” published on September 01, 2017, Seekingalpha.com published: “BioLineRX: Update And Preview Of The Company’s Q4 And FY 2016 Financial …” on March 22, 2017. More interesting news about Bioline RX Ltd (NASDAQ:BLRX) were released by: Seekingalpha.com and their article: “BiolineRx: COMBAT Engagement” published on April 19, 2017 as well as Seekingalpha.com‘s news article titled: “BioLineRx: At Around $1, This Sleeper Biotech Stock Is A Strong Buy” with publication date: July 13, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.